U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07138378) titled 'A Bioavailability Study of Nilotinib in Healthy, Adult, Human Subjects Under Fasted Conditions.' on July 29.
Brief Summary: An open label, single-center, balanced, randomized, four-treatment, four-sequence, four-period, single dose, crossover, comparative bioavailability study in healthy, adult, human subjects under fasteding conditions
Study Start Date: Nov. 15, 2024
Study Type: INTERVENTIONAL
Condition:
Cancer
Intervention:
DRUG: XS003 (nilotinib)
To evaluate the PK dose proportionality of Tasigna 200 mg versus Tasigna 400 mg and XS003 capsules 2x48mg (96mg) versus XS003 capsules 4x48mg (192mg).
DRUG: Tasigna (nilotinib)
...